🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05561088
Recruiting Not applicable

Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke

NCT05561088 · tracked via the Priya Life Science China tracker
Sponsor
Xi'an No.3 Hospital
Phase
Not applicable
Started
2023-04-27
Last updated
2023-05-12

Condition(s) studied

AcupunctureAcute Ischemic StrokeMechanical Thrombectomy

Investigational drug(s) / intervention(s)

Scalp AcupunctureThe treatment recommended in the guidelines for acute ischemic stroke was administered

Scalp Acupuncture: mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.

The treatment recommended in the guidelines for acute ischemic stroke was administered: The treatment recommended in the guidelines for acute ischemic stroke was administered

Study summary

To evaluate the efficacy and safety of head acupuncture combined with endovascular therapy for cerebral infarction compared with endovascular therapy alone

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years; * Patients with acute ischemic stroke who received endovascular treatment within 24 hours of onset; * 6 \< NIHSS ≤25; * ASPECT score ≥6 points; * Signed Informed consent. Exclusion Criteria: * CT or brain MRI confirmed intracranial tumor and intracranial hemorrhage; * Contraindications of contrast media; * Dementia or mental illness,unable to cooperate with treatment and follow-up; * The expected survival time was less than 3 months; * Women who are pregnant, planning to become pregnant or breastfeeding; * Currently participating in other clinical trials.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Xi 'an No.3 Hospital Xi'an Shaanxi Recruiting

More Xi'an No.3 Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05561088 on ClinicalTrials.gov ↗ ← All trials in China